- Oops!Something went wrong.Please try again later.
Achiko AG / Key word(s): Development of Sales
Achiko secures initial sales of AptameX Covid-19 diagnostic test
- Achiko has received its first purchase order in Jakarta and Bali in Indonesia.
- The orders translates to 20'000 tests - while modest in size the order is expected to pave the way to rapid adoption by other locations and countries.
- After consolidating the results of the first sales, the pilot project and the data from the first production, the platform will be quickly scaled and supplemented with additional products.
- Following the receipt of the CE marking, the expansion into further countries will be initiated.
Zurich, 27 October 2021: Ad hoc announcement pursuant to Art. 53 LR - On the heels of its announcements regarding a commercial pilot in Indonesia and initial production planning, Achiko AG (SWX: ACHI, ISIN CH0522213468) ("Achiko", the "Company") is proud to announce that it has successfully secured its first purchase orders of its Covid-19 testing platform and around 20,000 of its groundbreaking Covid-19 tests using AptameXTM.
"We're excited to be finally getting AptameX to market", said Steven Goh, CEO of Achiko AG. "To our minds, Indonesia is representative of the challenges that many low- and middle-income countries face when confronting Covid-19. As Covid-19 becomes endemic, we have a unique proposition by using a DNA aptamer rather than an antigen to deliver possibly a best in market test at a price point few others can meet. This is the first test kit on platform, and will hopefully be the start of many."
One of the largest countries in the world, Indonesia is a country with over 270 million people living in over 6,000 islands, speaking over 700 languages and has an indigenous population of over 70 million people.
The country was early to recognise the threat that Covid-19 posed, and the government has responded with a range of repeated measures from social distancing and testing to local therapeutics and vaccinations. A surge in cases and a jump in the death rates in the middle of 2021, brought about by the Delta variant, was met with lockdowns, a race to raise vaccination rates, and an increase in testing. In spite of this, vaccination rates in the country remain varied, with some places such as Bali, reporting vaccination rates amongst for people over 12 years of age to be over 80%, whilst the country as a whole reports the rate as over 30%.
Against this backdrop and with AptameX and Teman Sehat working well with other systems, the Company believes that it can play a role in restoring trust and confidence especially in workplaces, manufacturing, healthcare, education, recreation, tourism and other places.
Product Highlights and Implementation
Unlike other rapid testing formats which rely on an antigen and a nasal swab AptameX is a saliva-based test and uses a DNA aptamer, a synthetic strand of DNA, instead of an antigen to detect Covid-19. This innovation in chemistry opens the door to a structural advantage over other rapid tests. Indications in the lab show a greater sensitivity even at low viral loads. At a high industry CT score of 28.3, AptameX delivered a sensitivity of 77% (95% CI: 75.94 - 79.24). The Company is currently calibrating the production test in the field and will report on results later this year.
Teman Sehat has two parts. Firstly, it is integrated with AptameX and reorganises the diagnostics and billing process facilitating an easier testing process to lower the cost of testing to less than a few US-Dollars. Secondly, it offers check-ins on the app as a wrapper for tests, billing and providing public assurance for places. This second part can support external platforms including Pedulilindungi, the national certification system and offers advantages in payments, rewards and user experience.
Combined, AptameX and Teman Sehat has the unique selling points of ease of use, speed and cost to the end user. Comparatively, PCR testing is expensive and impractical in many cases, and many rapid tests have sensitivity issues and, whilst being cheaper than a PCR test, are still too expensive for frequent mass testing.
"From here, we intend to ensure that we can reliably manufacture, sell and deliver a great service in Indonesia", added Steven Goh. "It is certain by now that Covid-19 is going to be around for a long time, and we're in a good position to deliver assurance services to a wide range of workplaces and communities in Indonesia and everywhere else. First with AptameX as a leading product, followed by other complementary tests in the future. And with a CE Mark we expect to receive in the next few months, we're extremely well positioned to replicate the model to other countries soon."
AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialisation rights.
Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.
Further information can be found at www.achiko.com.
Switzerland & Global
U.S. & Global
End of ad hoc announcement
SIX Swiss Exchange
EQS News ID:
End of Announcement
EQS Group News Service